Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma

被引：0
|
作者：
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4114505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4114505
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Outcomes of ide-cel in patients with relapsed/refractory multiple myeloma: A single-institution experience
    Trando, Aaron
    Ghamsari, Farid
    Yeung, Philip
    Costello, Caitlin
    Saunders, Ila M.
    Jeong, Ah-Reum
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
    Frenking, Jan H.
    Zhou, Xiang
    Wagner, Vivien
    Hielscher, Thomas
    Kauer, Joseph
    Mai, Elias K.
    Friedrich, Mirco J.
    Michel, Christian S.
    Hajiyianni, Marina
    Breitkreutz, Iris
    Costello, Patrick
    Nadeem, Omar
    Weinhold, Niels
    Goldschmidt, Hartmut
    Schmitt, Anita
    Luft, Thomas
    Schmitt, Michael
    Mueller-Tidow, Carsten
    Topp, Max
    Einsele, Hermann
    Dreger, Peter
    Munshi, Nikhil C.
    Sperling, Adam S.
    Rasche, Leo
    Sauer, Sandra
    Raab, Marc S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)
  • [23] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    He, Shao-long
    Cheng, Yu-hang
    Wang, Di
    Xu, Meng-lei
    Que, Yi-mei
    Xu, Yan-jie
    Ma, Liang-ming
    Li, Chun-rui
    Zhou, Jian-feng
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 474 - 481
  • [24] EVALUATION OF HEALTH STATUS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), CAR T CELL THERAPY AGAINST BCMA
    Paula, Rodriguez-Otero
    Michel, Delforge
    Nina, Shah
    Parames-Waran, Hari
    Julia, Braverman
    Andrew, Trigg
    Payal, Patel
    Liping, Huang
    Kristen, Hege
    Sujith, Dhanasiri
    HAEMATOLOGICA, 2021, 106 (10) : 287 - 288
  • [25] Safety and Efficacy of Anti-Bcma CAR-T Cells for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Literature
    Khan, Israr
    Rafae, Abdul
    Javaid, Anum
    Ahmed, Zahoor
    Qadeer, Haifza Abeera
    Khan, Sana Irfan
    Dar, Abdul Jabbar
    Khurshid, Qasim
    Jaan, Ali
    Khalid, Farhan
    Aijaz, Zobia
    Hashmi, Mydah Sajid
    Malik, Mustafa Nadeem
    Anwer, Faiz
    BLOOD, 2020, 136
  • [26] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    Shao-long He
    Yu-hang Cheng
    Di Wang
    Meng-lei Xu
    Yi-mei Que
    Yan-jie Xu
    Liang-ming Ma
    Chun-rui Li
    Jian-feng Zhou
    Current Medical Science, 2021, 41 : 474 - 481
  • [27] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
    Anderson, Larry D., Jr.
    Munshi, Nikhil C.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
  • [29] Impact of Genetic Ancestry on Outcomes and Toxicity of Ide-cel in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dillard, Christen
    Hildebrandt, Michelle
    Lee, Hans
    Kalariya, Nilesh
    Subramanian, Naveen
    Pasvolsky, Oren
    Ferreri, Christopher
    Gaballa, Mahmoud
    Thomas, Sheeba
    Weber, Donna
    Becnel, Melody
    Kaufman, Gregory
    Chen, Jessica
    Hawkins, Misha
    Abreu, Michelly
    Qazilbash, Muzaffar
    Orlowski, Robert
    Patel, Krina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S49 - S50
  • [30] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
    Cavo, M.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I.
    Delforge, M.
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J.
    Patel, P.
    Huang, L.
    Campbell, T.
    Hege, K.
    Munshi, N.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
12345